Últimas noticias sobre Nevro (NYSE:NVRO) Bolsa

Nevro

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.

Nevro Corp

NEVRO ORD

Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) is set to give its latest quarterly earnings report on Monday, 2024-11-11. Here's what investors need to know before the announcement.
Analysts estimate that Nevro will report an earnings per share (EPS) of $-0.81. 
Investors in Nevro are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
The company's EPS beat by $0.15 in the last quarter, leading to a 44.42% drop in the share price on the following day.

<img src="https://www.benzinga.com/files/images/story/2024/1731074556_0.png" alt="eps graph" />
<h3>Nevro Share Price Analysis</h3>
Shares of Nevro were trading at $5.34 as of November 07. Over the last 52-week period, shares are down 65.01%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Views on Nevro</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Nevro.
Analysts have given Nevro a total of 1 ratings, with the consensus rating being Neutral. The average one-year price target is $6.0, indicating a potential 12.36% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Senseonics Holdings, NeuroPace and BrainsWay, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus outlook from analysts is an Buy trajectory for Senseonics Holdings, with an average 1-year price target of $2.0, indicating a potential 62.55% downside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for NeuroPace, with an average 1-year price target of $16.5, indicating a potential 208.99% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for BrainsWay, with an average 1-year price target of $14.83, implying a potential 177.72% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary presents essential metrics for Senseonics Holdings, NeuroPace and BrainsWay, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nevro</td>
<td>Neutral</td>
<td>-4.27%</td>
<td>$67.47M</td>
<td>-7.08%</td>
</tr>
<tr>
<td>Senseonics Holdings</td>
<td>Buy</td>
<td>17.91%</td>
<td>$298K</td>
<td>-207.65%</td>
</tr>
<tr>
<td>NeuroPace</td>
<td>Outperform</td>
<td>16.63%</td>
<td>$14.13M</td>
<td>-62.03%</td>
</tr>
<tr>
<td>BrainsWay</td>
<td>Buy</td>
<td>27.79%</td>
<td>$7.54M</td>
<td>1.41%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Nevro ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages. It also has the lowest Return on Equity among its peers. Overall, Nevro's performance is weaker compared to its peers in terms of financial metrics.
<h3>Unveiling the Story Behind Nevro</h3>
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
<h3>Financial Milestones: Nevro's Journey</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Negative Revenue Trend: Examining Nevro's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -4.27% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Nevro's net margin excels beyond industry benchmarks, reaching -18.79%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -7.08%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Nevro's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -3.26%, the company showcases efficient use of assets and strong financial health.
Debt Management: Nevro's debt-to-equity ratio is below the industry average at 0.88, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/NVRO/earnings">To track all earnings releases for Nevro visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

NVRO

A Look Ahead: Nevro's Earnings Forecast

News

Nevro Corp Announced The Publication Of New Data In The Journal Of Pain Research With Encouraging Results Regarding Pain Relief And Long Term Meaningful Reductions in A1C

Ratings for Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $7.31, along with a high estimate of $10.00 and a low estimate of $5.50. A decline of 36.05% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1727816477_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Nevro among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$6.89</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$6.89</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$5.50</td>
<td>$10.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$7.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Nathan Treybeck</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$5.50</td>
<td>$13.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$8.20</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nevro. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Nevro compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Nevro's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Nevro's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NVRO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nevro analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Nevro's Background</h2>
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
<h3>Financial Milestones: Nevro's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Nevro faced challenges, resulting in a decline of approximately -4.27% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Nevro's net margin is impressive, surpassing industry averages. With a net margin of -18.79%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Nevro's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -7.08%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Nevro's ROA stands out, surpassing industry averages. With an impressive ROA of -3.26%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Nevro's debt-to-equity ratio is below the industry average. With a ratio of 0.88, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Nevro: 10 Analysts Share Their Views

Citigroup analyst Joanne Wuensch maintains Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) with a Neutral and lowers the price target from $6.89 to $6.

Price Target

Citigroup Maintains Neutral on Nevro, Lowers Price Target to $6

Nevro Launches AI-Driven HFX AdaptivAI, The First AI-Powered Spinal Cord Stimulation Technology, Following FDA Approval For Personalized Pain Relief

Citigroup analyst Joanne Wuensch upgrades Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) from Sell to Neutral and announces $6.89 price target.

Upgrades

Citigroup Upgrades Nevro to Neutral, Announces $6.89 Price Target

Wolfe Research analyst Mike Polark upgrades Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) from Underperform to Peer Perform.

Wolfe Research Upgrades Nevro to Peer Perform

In the last three months, 9 analysts have published ratings on Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.69, a high estimate of $10.00, and a low estimate of $5.50. Highlighting a 36.81% decrease, the current average has fallen from the previous average price target of $12.17. 
<img src="https://www.benzinga.com/files/images/story/2024/1723122087_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Nevro by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$5.50</td>
<td>$10.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$7.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Nathan Treybeck</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$5.50</td>
<td>$13.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$8.20</td>
<td>$9.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$9.00</td>
<td>$13.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nevro. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Nevro compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Nevro's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Nevro's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NVRO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nevro analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Nevro</h2>
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
<h3>Nevro: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Nevro's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -4.27% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Nevro's net margin excels beyond industry benchmarks, reaching -18.79%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -7.08%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Nevro's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.26% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Nevro's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.88.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Nevro: Insights From 9 Financial Analysts

Truist Securities analyst Richard Newitter maintains Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) with a Hold and lowers the price target from $10 to $5.5.

Truist Securities Maintains Hold on Nevro, Lowers Price Target to $5.5

JMP Securities analyst David Turkaly downgrades Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) from Market Outperform to Market Perform.

Downgrades

JMP Securities Downgrades Nevro to Market Perform

In the latest quarter, 8 analysts provided ratings for Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.96, a high estimate of $10.00, and a low estimate of $5.50. Experiencing a 36.01% decline, the current average is now lower than the previous average price target of $12.44. 
<img src="https://www.benzinga.com/files/images/story/2024/1723053873_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Nevro is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$7.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Nathan Treybeck</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$5.50</td>
<td>$13.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$8.20</td>
<td>$9.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$9.00</td>
<td>$13.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nevro. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Nevro compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Nevro's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Nevro's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NVRO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nevro analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Nevro's Background</h2>
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
<h3>Understanding the Numbers: Nevro's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Nevro showcased positive performance, achieving a revenue growth rate of 5.78% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -24.94%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Nevro's ROE excels beyond industry benchmarks, reaching -8.89%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -4.13%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.78, Nevro adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Nevro: Insights From 8 Financial Analysts

RBC Capital analyst Shagun Singh maintains Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) with a Sector Perform and lowers the price target from $16 to $7.

RBC Capital Maintains Sector Perform on Nevro, Lowers Price Target to $7

Baird analyst Mike Polark maintains Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) with a Neutral and lowers the price target from $11 to $8.

Baird Maintains Neutral on Nevro, Lowers Price Target to $8

U.S. stock futures were higher this morning, with the Dow futures gaining around 300 points on Wednesday.
Shares of Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) dipped 15.8% to $109.68 after the company reported worse-than-expected second-quarter EPS results and issued third-quarter revenue <a href="https://www.benzinga.com/markets/equities/24/08/40213199/why-airbnb-stock-is-down-16-in-wednesday-pre-market">guidance below estimates</a>.
Airbnb's second-quarter sales of $2.748 billion exceeded the analyst consensus estimate of $2.738 billion, marking a 10.63% increase from the same period last year. However, the company's quarterly GAAP earnings of 86 cents per share fell short of the analyst consensus estimate of 92 cents, missing the mark by 6.52%.
ZoomInfo Technologies shares dipped 15.2% to $8.31 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares dipped 36.2% to $6.27 in pre-market trading after posting a loss for the second quarter.</li>
<li>Nevro Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares declined 31.1% to $5.99 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>National Vision Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) dipped 24.8% to $10.50 in pre-market trading following weak quarterly sales.</li>
<li>Cryoport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) shares slipped 23.5% to $5.95 in pre-market trading after posting weak quarterly sales.</li>
<li>The RealReal, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>) dipped 19.4% to $2.50 in pre-market trading following second-quarter results.</li>
<li>Trex Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) fell 16.7% to $63.75 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) dipped 16.7% to $15.70 following second-quarter results.</li>
<li>Progyny, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) fell 16.5% to $21.48 in pre-market trading after the company reported worse-than-expected second-quarter revenue results.</li>
<li>Tripadvisor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) fell 15.4% to $13.80 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) shares declined 14.2% to $9.41 following second-quarter financial results.</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) dipped 8.1% to $13.60 after the company reported worse-than-expected quarterly adjusted EPS results.</li>
<li>Ashland Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) dipped 6.2% to $84.78 following weak quarterly sales.</li>
<li>Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) fell 3.8% to $113.05.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40194186/top-4-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 4 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABNB

ACAD

CYRX

EXPE

LYFT

PGNY

REAL

RIVN

TREX

TRIP

Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Wells Fargo analyst Nathan Treybeck downgrades Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) from Equal-Weight to Underweight and lowers the price target from $13 to $5.5.

Wells Fargo Downgrades Nevro to Underweight, Lowers Price Target to $5.5

JP Morgan analyst Robbie Marcus downgrades Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) from Neutral to Underweight.

JP Morgan Downgrades Nevro to Underweight

WIIM

Nevro shares are trading lower after the company reported worse-than-expected Q2 sales results. Also, Piper Sandler maintained an Underweight rating on the stock and lowered its price target from $12 to $7.

Piper Sandler analyst Adam Maeder maintains Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) with a Underweight and lowers the price target from $12 to $7.

Piper Sandler Maintains Underweight on Nevro, Lowers Price Target to $7

Shares of Fortinet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and<a href="https://www.benzinga.com/news/earnings/24/08/40203474/fortinet-q2-earnings-revenue-beat-eps-beat-strong-guidance-and-more"> issued guidance above estimates.</a>
Fortinet's second-quarter revenue increased 11% year-over-year to $1.43 billion, beating consensus estimates of $1.403 billion. The cybersecurity company reported second-quarter adjusted earnings of 57 cents per share, beating analyst estimates of 41 cents per share.
Fortinet shares jumped 17% to $65.29 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) rose 68.1% to $0.6220 in today's pre-market trading after dipping around 74% on Tuesday.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) gained 43% to $7.15 in pre-market trading after the company reported better-than-expected second-quarter revenue results.</li>
<li>Zhongchao Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) gained 34.2% to $1.65 in pre-market trading.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) jumped 24% to $29.60 in pre-market trading after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates.</li>
<li>Latham Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) shares gained 20.6% to $3.75 in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates. Additionally, the company announced an acquisition of Coverstar Central.</li>
<li>Mynd.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYND#NYSE">MYND</a>) shares rose 15.9% to $2.55 in pre-market trading after falling around 7% on Tuesday.</li>
<li>Beyond Air, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares rose 14.3% to $0.5770 in pre-market trading after the company reported better-than-expected quarterly EPS results.</li>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) gained 12.8% to $0.5756 in pre-market trading after jumping around 13% on Tuesday.</li>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares gained 10% to $3.30 in pre-market trading after the company reported a narrower-than-expected quarterly loss.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Scorpius Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#NYSE">SCPX</a>) shares dipped 77% to $1.30 in pre-market trading after gaining 19% on Tuesday. Scorpius announced that it has surpassed $100 million in near-term business development opportunities across government and commercial sectors.</li>
<li>Talis Biomedical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLIS#NASDAQ">TLIS</a>) shares declined 52.7% to $4.25 in pre-market trading after the company initiated a board restructuring.</li>
<li>Porch Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) declined 38.2% to $1.07 in pre-market trading after reporting weak quarterly results.</li>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) shares declined 37.1% to $0.6274 in pre-market trading after the company reported mixed second-quarter financial results.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares fell 36.2% to $6.27 in pre-market trading after posting a loss for the second quarter.</li>
<li>DZS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DZSI#NASDAQ">DZSI</a>) fell 36.2% to $0.66 pre-market trading after the company announced it received a delisting notice from the Nasdaq.</li>
<li>VBI Vaccines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIV#NASDAQ">VBIV</a>) fell 32.2% to $0.09 in today's pre-market trading after jumping 111% on Tuesday.</li>
<li>Nevro Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares fell 31.1% to $5.99 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) fell 24.5% to $2.90 in pre-market trading after declining around 11% on Tuesday.</li>
<li>Cryoport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) shares fell 23.5% to $5.95 in pre-market trading after posting weak quarterly sales.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40194186/top-4-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 4 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

CRVS

DZSI

FTNT

LITM

LUMN

MYND

PRCH

SCPX

STEM

SWIM

TLIS

UPST

VBIV

XAIR

ZCMD

Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Guidance

Nevro Sees Q3 2024 Worldwide Revenue $92M-$94M

J&J, Stryker among potential suitors for Nevro: Wolfe

In a report released today, Joanne Wuensch from Citi upgraded Nevro Corp (NVRO – Research Report) to a Hold, with a price target of $6.89. Joanne W...

Hold Rating on Nevro Corp Amid Reduced Revenue Forecast and Market Uncertainty

Nevro: Not Having My Back

Citi upgrades Nevro to neutral following sell-off

Nevro Corp (NVRO – Research Report) received a Sell rating and price target from J.P. Morgan analyst Robbie Marcus yesterday. The company's shares ...

J.P. Morgan downgrades Nevro Corp (NVRO) to a Sell

RBC Capital analyst Shagun Singh Chadha maintained a Hold rating on Nevro Corp (NVRO – Research Report) today and set a price target of $7.00. The ...

RBC Capital Keeps Their Hold Rating on Nevro Corp (NVRO)

In a report released on August 30, Travis Steed from Bank of America Securities reiterated a Sell rating on Nevro Corp (NVRO – Research Report), wi...

Nevro Corp: Underperform Rating with Reduced Price Objective Amid Revenue Decline and Market Challenges

Wells Fargo analyst Nathan Treybeck has maintained their bearish stance on NVRO stock, giving a Sell rating on August 30. Nathan Treybeck's rating ...

Nevro Corp: Strategic Uncertainty and Competitive Pressures Prompt Sell Rating

In a report released on October 8, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Nevro Corp (NVRO – Research Report), with a pri...

RBC Capital Sticks to Its Hold Rating for Nevro Corp (NVRO)

Nevro (NVRO) announced the publication of new data in the Journal of Pain Research demonstrating significant, durable pain relief and long-term and...

Nevro announces publication of new data from SCS stimulation study

ATEC

GMED

Press Releases

Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024

Contracts

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Nevro Reports Second-Quarter 2024 Financial Results

Nevro to Present at Wells Fargo 2024 Healthcare Conference

Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation

Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024

New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy

AngioDynamics

Accuray

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

BrainsWay Ltd. - American Depositary Shares

BrainsWay

Alpha Tau Medical

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Nevro

Noticias

Últimas noticias sobre Nevro (NYSE:NVRO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL